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Over the last two decades, management of acute myocardial
infarction (MI) has shifted from a “wait and watch” strategy
to an increasingly aggressive strategy of restoring and
maintaining (e.g., thrombolytics, antiplatelet agents) early
patency to the infarct-related vessel and to other approaches
that directly protect the myocardium (e.g., beta-blockers,
angiotensin-converting enzyme inhibitors). Improved out-
comes in MI have been achieved largely by using a combi-
nation of simple pharmacologic therapies and by the intro-
duction of specialized coronary care units (1). In recent years
advances in catheter based technologies have improved
reperfusion success in MI patients with ST elevation.
Randomized clinical trials of primary balloon percutaneous
transluminal coronary angioplasty (PTCA) versus thrombo-
lytic therapy have demonstrated that primary PTCA results
in higher rates of coronary patency and lower rates of stroke,
reinfarction and death (2). However, the relative benefit of
PTCA over thrombolytic therapy is still unknown in a
community setting in which access to catheterization labo-
ratories (cath labs) and operator expertise is less uniform
than in the trial setting (3). Whether immediate availability
of invasive facilities, compared with referral of sick or
high-risk patients to offsite cath labs, will improve outcomes
is not known. This question has important medical, orga-
nizational, cost and training implications.
Rogers et al. (4) attempt to answer this question using
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data from a large registry of 1,506 U.S. hospitals that
represent a spectrum of hospital types (noninvasive, cath-
capable, PTCA-capable, coronary artery bypass graft-
capable) and regions. They observed that the time to
thrombolytic therapy was similar among the four types of
hospitals and, as expected, that a greater proportion of
patients initially presenting to hospitals capable of cardiac
catheterization received invasive therapy but a greater pro-
portion of those admitted to noninvasive centers was trans-
ferred. However, the primary mode of reperfusion was still
thrombolytic therapy in each of the four categories of
patients. One would expect that availability of immediate
PTCA would allow additional patients not eligible for
thrombolytic therapy to receive a catheter based interven-
tion. However, the overall rates of reperfusion attempts
were not significantly different among the four types of
hospitals, and the risk profiles of the patients receiving
reperfusion treatment (i.e., either thrombolytic or PTCA)
treated in hospitals with and without PTCA facilities were
similar. Consequently in the approximately 10% of patients
for whom out-of-hospital data are available, 90-day survival
after discharge was not significantly different whether or not
invasive facilities were available. Although the follow-up
data are limited and only short-term, they are consistent
with the hypothesis that the initial management of MI does
not differ whether or not invasive facilities are available on
site. This is consistent with other studies that show that
availability of catheterization facilities does not broaden the
types or increase the risk profiles of patients to be treated
(5). Paradoxically, lower risk patients are more often se-
lected to undergo catheterization. This bias reduces the
potential benefits of invasive therapies, first by subjecting
lower risk patients to a therapy they may not necessarily
need—thereby resulting in higher peri-procedural compli-
cations (major bleeds, strokes and mortality)—and second,
by not delivering the most aggressive care to the highest risk
patients, who stand to benefit the most.
Before embarking on newer and more costly treatment
strategies, perhaps efforts should be directed at optimizing
the use of proven therapies. Such an approach is more likely
to lead to a greater benefit. For instance, the average time to
thrombolytic therapy across all hospital groups in this study
(42 min) is still longer than recommended (1,6). Efforts
should be directed at continuously monitoring this variable
and providing these data to local physicians at each center in
an effort to improve the performance of those providing
first-line therapy. Emergency personnel should also be
appropriately trained in the early recognition of those
patients who are at high risk and require immediate transfer
to a facility with invasive capability. This will improve the
selection for those patients who require invasive manage-
ment and therefore improve the impact of these therapies.
Although there may be, at best, modest benefits of one
thrombolytic agent versus another (e.g., tissue plasminogen
activator vs. streptokinase), the most important determinant
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of outcome is not which agent to use but, rather, whether a
thrombolytic agent is indicated and, if so, how soon it is
administered. Newer data, with combinations of thrombo-
lytic agents and platelet GPIIb/IIIa receptor inhibitors or
bolus administration of new generation thrombolytics, sug-
gest that 90-min patency rates may be enhanced and
approach those achieved with primary PTCA (7,8). How-
ever, these therapies are limited by the higher rates of
intracranial bleeds and their high costs (both direct and
indirect). In contrast, previous data from several sources indi-
cate underutilization of proven and less expensive therapies
(e.g., aspirin, beta-blockers or lipid lowering).
The study by Rogers et al. (4) does not distinguish
between the management of MI patients presenting with
and without ST elevation on the initial electrocardiogram.
Patients without ST elevation MI tend to be older, have
higher rates of three-vessel disease, diabetes and previous
MI and consequently have higher mortality and heart
failure. Unlike MI with ST elevation, it may be more
difficult to identify the culprit lesion, and thrombolytic
therapy has been shown to worsen outcome. Supporters of
an invasive strategy argue that there are several benefits to
catheterization, including: 1) early identification of surgical
disease, including left main lesions; 2) early identification of
non-coronary disease, so that the risks of prolonged anti-
thrombin or antiplatelet therapy can be reduced; 3) potential
cost savings in terms of hospital length of stay; and 4)
reduced angina. However, studies randomizing patients to
routine early catheterization versus selective catheterization
based on failure of medical management or spontaneous
ischemia do not show a significant benefit in terms of death
or MI in favor of the invasive arm (9,10). Indeed some
studies indicated a worse outcome (10). In the two studies
that suggested a long-term benefit of death and MI in the
invasive strategy (11,12), the intervention was either selec-
tive or was performed a few days or even weeks later, thus
allowing the patient to be first stabilized medically.
Substantial improvements in the management of MI
patients will result from organizational and system changes
that lead to rapid and more widespread use of proven and
relatively simple therapies (i.e., improving patient recogni-
tion of chest pain, early presentation to emergency room,
improving door to needle time of thrombolytic therapy and
use of early aspirin, beta blockers and angiotensin-converting
enzyme inhibitors in appropriate patients). A small change in
these factors (e.g., a 10-min decrease in door to needle time
across the U.S. or a 10% increase in use of aspirin, beta blocker,
or lipid lowering therapy) is likely to have a large beneficial
effect in improving outcomes of MI patients (13).
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